)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nanosonics
Nanosonics (NAN) investor relations material
Nanosonics AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary4 Nov, 2026
Opening remarks and agenda
The 20th AGM opened with a quorum; 293 valid proxies represented more than 190 million shares, just over 64% of shares on issue.
Chairman Steven Sargent and CEO Michael Kavanagh delivered their addresses; proceedings included eight resolutions, questions and votes, followed by stakeholder questions.
Annual reports for the year ended 30 June 2026 were received for consideration without a formal vote.
Financial performance review
FY26 reported revenue was $203.9m, up 3%; constant-currency revenue was $211.5m, up 6%. Constant-currency EBIT rose 21% to $21.6m; gross margin was 76.9%, or 77.6% at constant currency.
Trophon placements were 4,230, up 9%, and the installed base grew 6% to 39,230 devices; trophon-only EBIT was $50.6m, up 5%, or $56.5m at constant currency, up 16%.
Cash was $155.2m with no debt; R&D investment was $31.8m and operating expenses were $141.4m, up 2%. Management cited disciplined costs, cash generation and capacity to invest in R&D and CORIS.
More than 31 million patients were protected in FY26; milestones included trophon3 and trophon2 Plus launches and an AUD 20m buyback.
Board and executive committee updates
Sarah Butler joined as an independent non-executive director in January 2026 and was nominated for election with Board support.
Julien Sauvagnargues was announced as an independent non-executive director, joining on 1 December 2026; he brings two decades at Olympus and MedTech leadership experience across Europe and North America.
Dr. Lisa McIntyre left the Board in November 2025; shareholders were also asked to re-elect Larry Marshall and Tracey Batten.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nanosonics
- FY27 guidance targets 8–12% revenue growth, increased CORIS investment, and a $40M buyback.NAN
H2 2026 - Revenue up 9% to $102.2M, operating margin up 27%, guidance and strong cash position maintained.NANH1 2026
- Strong financials, product innovation, and global expansion drive growth; $20M buyback announced.NANAGM 2025
- Strong FY25 growth with 17% revenue increase and robust outlook for FY26.NANH2 2025
- Revenue up 2%, installed base grew 7%, and all resolutions passed strongly.NANAGM 2024
- Strong H2 rebound drove 2% revenue growth; FY25 targets 8–12% growth and margin recovery.NANH2 2024
- Revenue up 18%, net profit up 58%, gross margin 78.5%, FY25 guidance raised.NANH1 2025
Next Nanosonics earnings date
H1 202723 Feb, 2027
Nanosonics
Next Nanosonics earnings date
H1 202723 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Nanosonics Limited is a infections prevention company operating in Australia and internationally. Using its unique drug-free approach, Nanosonics has developed a suite of products that fight bacteria directly, removing the risk of bacterial resistance to antibiotics. Nanosonics' lead product, NeutrAvidin®, helps prevent infections in selected groups of patients, including surgery patients with open wounds, endoscopy patients and catheter dwellers, who may be at risk of infection. The company's Infection Prevention Products and Services helps commercial, health care, education and hospitality industries.